Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis

被引:132
作者
Mehanna, Hisham [1 ,22 ]
Taberna, Miren [2 ,3 ,4 ]
von Buchwald, Christian [6 ]
Tous, Sara [3 ,5 ]
Brooks, Jill [1 ]
Mena, Marisa [3 ,5 ]
Morey, Francisca [3 ]
Gronhoj, Christian [6 ]
Rasmussen, Jacob Hoygaard [6 ]
Garset-Zamani, Martin [6 ]
Bruni, Laia [3 ,5 ]
Batis, Nikolaos [1 ]
Brakenhoff, Ruud H. [7 ]
Leemans, C. Rene [7 ]
Jong, Robert J. Baatenburg de [8 ]
Klussmann, Jens Peter [9 ]
Wuerdemann, Nora [9 ]
Wagner, Steffen [10 ]
Dalianis, Tina [11 ]
Marklund, Linda [12 ,13 ,14 ]
Mirghani, Haitham [15 ]
Schache, Andrew [16 ]
James, Jaqueline A. [17 ,18 ]
Huang, Shao Hui [19 ]
O'Sullivan, Brian [19 ]
Nankivell, Paul [1 ]
Broglie, Martina A. [20 ]
Hoffmann, Markus [21 ]
Quabius, Elgar Susanne [21 ]
Alemany, Laia [3 ,5 ]
机构
[1] Univ Birmingham, Inst Head Neck Studies & Educ InHANSE, Inst Canc & Genom Sci, Birmingham, England
[2] Inst Invest Biomed Bellvitge IDIBELL, Dept Med Oncol, Barcelona, Spain
[3] Inst Invest Biomed Bellvitge IDIBELL, Catalan Inst Oncol ICO, Canc Epidemiol Res Programme, Barcelona, Spain
[4] Univ Barcelona, Dept Med, Barcelona, Spain
[5] Inst Salud Carlos III, Epidemiol & Publ Hlth, Ctr Invest Biomed Red Epidemiol & Salud Publ CIBER, Madrid, Spain
[6] Copenhagen Univ Hosp, Dept Otolaryngol Head & Neck Surg & Audiol, Rigshosp, Copenhagen, Denmark
[7] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Otolaryngol head & neck Surg, Amsterdam UMC, Amsterdam, Netherlands
[8] Erasmus MC Canc Ctr, Dept Otolaryngol Head & Neck Surg, Rotterdam, Netherlands
[9] Univ Cologne, Med Fac, Dept Otorhinolaryngol Head & Neck Surg, Cologne, Germany
[10] Univ Giessen, Dept Otorhinolaryngol Head & Neck Surg, Giessen, Germany
[11] Karolinska Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden
[12] Karolinska Univ Hosp, Dept Clin Sci Intervent & Technol, Dept Oto Rhinolaryngol Head & Neck Surg, Stockholm, Sweden
[13] Karolinska Univ Hosp, Med Unit Head & Neck, Lung & Skin Canc, Stockholm, Sweden
[14] Uppsala Univ, Dept Surg Sci, Sect Otolaryngol & Head & Neck Surg, Uppsala, Sweden
[15] Gustave Roussy Canc Campus, Dept Head & Neck Oncol, Villejuif, France
[16] Univ Liverpool, Liverpool Head & Neck Ctr, Dept Mol & Clin Canc Med, Liverpool, England
[17] Queens Univ Belfast, Precis Med Ctr Excellence, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland
[18] Belfast Hlth & Social Care Trust, Reg Mol Diagnost Serv, Belfast, North Ireland
[19] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol Otolaryngol Head & Neck Surg, Toronto, ON, Canada
[20] Univ Zurich, Univ Hosp Zurich, Dept Otorhinolaryngol Head & Neck Surg, Zurich, Switzerland
[21] Christian Albrechts Univ Kiel, Dept Otorhinolaryngol Head & Neck Surg, Kiel, Germany
[22] Univ Birmingham, Inst Head Neck Studies & Educ InHANSE, Inst Canc & Genom Sci, Birmingham B15 2TT, England
基金
英国医学研究理事会;
关键词
HUMAN-PAPILLOMAVIRUS; MESSENGER-RNA; NECK-CANCER; SURVIVAL; HEAD; P16(INK4A); CARCINOMAS; TONSILLAR; DNA; EXPRESSION;
D O I
10.1016/S1470-2045(23)00013-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background p16(INK4a) (p16) immunohistochemistry is the most widely used biomarker assay for inferring HPV causation in oropharyngeal cancer in clinical and trial settings. However, discordance exists between p16 and HPV DNA or RNA status in some patients with oropharyngeal cancer. We aimed to clearly quantify the extent of discordance, and its prognostic implications. Methods In this multicentre, multinational individual patient data analysis, we did a literature search in PubMed and Cochrane database for systematic reviews and original studies published in English between Jan 1, 1970, and Sept 30, 2022. We included retrospective series and prospective cohorts of consecutively recruited patients previously analysed in individual studies with minimum cohort size of 100 patients with primary squamous cell carcinoma of the oropharynx. Patient inclusion criteria were diagnosis with a primary squamous cell carcinoma of oropharyngeal cancer; data on p16 immunohistochemistry and on HPV testing; information on age, sex, tobacco, and alcohol use; staging by TNM 7th edition; information on treatments received; and data on clinical outcomes and follow-up (date of last follow-up if alive, date of recurrence or metastasis, and date and cause of death). There were no limits on age or performance status. The primary outcomes were the proportion of patients of the overall cohort who showed the different p16 and HPV result combinations, as well as 5-year overall survival and 5-year disease-free survival. Patients with recurrent or metastatic disease or who were treated palliatively were excluded from overall survival and disease-free survival analyses. Multivariable analysis models were used to calculate adjusted hazard ratios (aHR) for different p16 and HPV testing methods for overall survival, adjusted for prespecified confounding factors. Findings Our search returned 13 eligible studies that provided individual data for 13 cohorts of patients with oropharyngeal cancer from the UK, Canada, Denmark, Sweden, France, Germany, the Netherlands, Switzerland, and Spain. 7895 patients with oropharyngeal cancer were assessed for eligibility. 241 were excluded before analysis, and 7654 were eligible for p16 and HPV analysis. 5714 (74middot7%) of 7654 patients were male and 1940 (25middot3%) were female. Ethnicity data were not reported. 3805 patients were p16-positive, 415 (10middot9%) of whom were HPV-negative. This proportion differed significantly by geographical region and was highest in the areas with lowest HPV-attributable fractions (r=-0middot744, p=0middot0035). The proportion of patients with p16+/HPV- oropharyngeal cancer was highest in subsites outside the tonsil and base of tongue (29middot7% vs 9middot0%, p<0middot0001). 5-year overall survival was 81middot1% (95% CI 79middot5-82middot7) for p16+/HPV+, 40middot4% (38middot6-42middot4) for p16-/HPV-, 53middot2% (46middot6-60middot8) for p16-/HPV+, and 54middot7% (49middot2-60middot9) for p16+/HPV-. 5-year disease-free survival was 84middot3% (95% CI 82middot9-85middot7) for p16+/HPV+, 60middot8% (58middot8-62middot9) for p16-/HPV-; 71middot1% (64middot7-78middot2) for p16-/HPV+, and 67middot9% (62middot5-73middot7) for p16+/HPV-. Results were similar across all European sub-regions, but there were insufficient numbers of discordant patients from North America to draw conclusions in this cohort. Interpretation Patients with discordant oropharyngeal cancer (p16-/HPV+ or p16+/HPV-) had a significantly worse prognosis than patients with p16+/HPV+ oropharyngeal cancer, and a significantly better prognosis than patients with p16-/HPV- oropharyngeal cancer. Along with routine p16 immunohistochemistry, HPV testing should be mandated for clinical trials for all patients (or at least following a positive p16 test), and is recommended where HPV status might influence patient care, especially in areas with low HPV-attributable fractions. Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:239 / 251
页数:13
相关论文
共 29 条
  • [11] HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer - How valid is p16INK4A as surrogate marker?
    Hoffmann, Markus
    Tribius, Silke
    Quabius, Elgar Susanne
    Henry, Hannes
    Pfannenschmidt, Saskia
    Burkhardt, Claudia
    Goeroegh, Tibor
    Halec, Gordana
    Hoffmann, Anna Sophie
    Kahn, Tomas
    Roecken, Christoph
    Haag, Jochen
    Waterboer, Tim
    Schmitt, Markus
    [J]. CANCER LETTERS, 2012, 323 (01) : 88 - 96
  • [12] IARC, 2007, IARC MONOGRAPHS EVAL, V89, P223
  • [13] Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus
    Klussmann, JP
    Gültekin, E
    Weissenborn, SJ
    Wieland, U
    Dries, V
    Dienes, HP
    Eckel, HE
    Pfister, HJ
    Fuchs, PG
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (03) : 747 - 753
  • [14] Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review
    Larsen, C. Gronhoj
    Gyldenlove, M.
    Jensen, D. H.
    Therkildsen, M. H.
    Kiss, K.
    Norrild, B.
    Konge, L.
    von Buchwald, C.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1587 - 1594
  • [15] Human Papillomavirus Testing in Head and Neck Carcinomas Guideline From the College of American Pathologists
    Lewis, James S., Jr.
    Beadle, Beth
    Bishop, Justin A.
    Chernock, Rebecca D.
    Colasacco, Carol
    Lacchetti, Christina
    Moncur, Joel Todd
    Rocco, James W.
    Schwartz, Mary R.
    Seethala, Raja R.
    Thomas, Nicole E.
    Westra, William H.
    Faquin, William C.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (05) : 559 - 597
  • [16] Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8-Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas
    Marklund, Linda
    Holzhauser, Stefan
    de Flon, Caroline
    Zupancic, Mark
    Landin, David
    Kolev, Aeneas
    Haeggblom, Linnea
    Munck-Wikland, Eva
    Hammarstedt-Nordenvall, Lalle
    Dalianis, Tina
    Nasman, Anders
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 139 : 192 - 200
  • [17] Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer
    Marklund, Linda
    Nasman, Anders
    Ramqvist, Torbjorn
    Dalianis, Tina
    Munck-Wikland, Eva
    Hammarstedt, Lalle
    [J]. CANCER MEDICINE, 2012, 1 (01): : 82 - 88
  • [18] Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines
    McLaughlin-Drubin, Margaret E.
    Park, Donglim
    Munger, Karl
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (40) : 16175 - 16180
  • [19] Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
    Mehanna, Hisham
    Robinson, Max
    Hartley, Andrew
    Kong, Anthony
    Foran, Bernadette
    Fulton-Lieuw, Tessa
    Dalby, Matthew
    Mistry, Pankaj
    Sen, Mehmet
    O'Toole, Lorcan
    Al Booz, Hoda
    Dyker, Karen
    Moleron, Rafael
    Whitaker, Stephen
    Brennan, Sinead
    Cook, Audrey
    Griffin, Matthew
    Aynsley, Eleanor
    Rolles, Martin
    De Winton, Emma
    Chan, Andrew
    Srinivasan, Devraj
    Nixon, Ioanna
    Grumett, Joanne
    Leemans, C. Rene
    Buter, Jan
    Henderson, Julia
    Harrington, Kevin
    McConkey, Christopher
    Gray, Alastair
    Dunn, Janet
    [J]. LANCET, 2019, 393 (10166) : 51 - 60
  • [20] Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials
    Mehanna, Hisham
    Franklin, Natalie
    Compton, Natalie
    Robinson, Max
    Powell, Ned
    Biswas-Baldwin, Nigel
    Paleri, Vindh
    Hartley, Andrew
    Fresco, Lydia
    Al-Booz, Hoda
    Junor, Elizabeth
    El-Hariry, Iman
    Roberts, Sally
    Harrington, Kevin
    Ang, K. Kian
    Dunn, Janet
    Woodman, Ciaran
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E1863 - E1869